Skip to content

Prevalence of Hypogonadism in Male Cancer Patients

Prevalence of Hypogonadism in Male Cancer Patients

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00472940
Enrollment
135
Registered
2007-05-14
Start date
2006-11-30
Completion date
2020-09-02
Last updated
2020-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer, Hypogonadism

Keywords

Cancer, Hypogonadism, testosterone, cachexia

Brief summary

Cancer and its complications are common problems. In most cases, this condition has a profound impact on survival and quality of life (QoL). Fatigue, sexual dysfunction, decreased sexual drive, depression and poor appetite are commonly seen in these patients. However, these symptoms also are seen in men with other conditions including those with low testosterone levels. The objective of this study is to determine the number of male patients with cancer that have low testosterone levels and to establish the relationship between testosterone levels and the symptoms that these patients experience.

Interventions

None listed

Sponsors

Michael E. DeBakey VA Medical Center
CollaboratorFED
Solvay Pharmaceuticals
CollaboratorINDUSTRY
Baylor College of Medicine
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Male subjects ≥ 18 years of age with histological diagnosis of cancer for cancer group. 2. Provide written informed consent prior to screening. 3. Histological diagnosis of cancer other than non-melanoma skin cancer for the two cancer groups.

Exclusion criteria

1. Concomitant use of GH, Megestrol, Marinol, or any other anabolic agent, appetite stimulant (including corticosteroids other than dexamethasone at the time of IV chemotherapy administrations), tube feedings, or parenteral nutrition during the 3 months prior to entering the study. 2. Participation in a clinical trial with investigational agents within 1 month of enrollment. 3. Prior or current use of other medications that interfere with gonadal axis (androgens, estrogens, anti-androgens, etc).

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026